[go: up one dir, main page]

MX2021014350A - Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. - Google Patents

Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.

Info

Publication number
MX2021014350A
MX2021014350A MX2021014350A MX2021014350A MX2021014350A MX 2021014350 A MX2021014350 A MX 2021014350A MX 2021014350 A MX2021014350 A MX 2021014350A MX 2021014350 A MX2021014350 A MX 2021014350A MX 2021014350 A MX2021014350 A MX 2021014350A
Authority
MX
Mexico
Prior art keywords
isoindoline
oxo
compositions
methods
compounds
Prior art date
Application number
MX2021014350A
Other languages
English (en)
Inventor
Mark A Nagy
Joshua Hansen
Gang Lu
Matthew D Correa
Frans Baculi
Katherine Northcote
Laurie A Lebrun
Chin-Chun Lu
Sophie Peng
Sophie Perrin-Ninkovic
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2021014350A publication Critical patent/MX2021014350A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan en la presente compuestos de 1-oxo-isoindolin-5-ca rboxamida que tienen la siguiente estructura: (ver Fórmula) en donde R1, R2, R3, R4 y n son como se definen en la presente, composiciones que comprenden una cantidad eficaz de un compuesto de 1-oxo-isoindolin-5-carboxamida, y métodos para tratar o prevenir trastornos.
MX2021014350A 2019-05-31 2020-05-29 Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. MX2021014350A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855619P 2019-05-31 2019-05-31
PCT/US2020/035043 WO2020243379A1 (en) 2019-05-31 2020-05-29 Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
MX2021014350A true MX2021014350A (es) 2022-02-21

Family

ID=73551319

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014350A MX2021014350A (es) 2019-05-31 2020-05-29 Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.

Country Status (19)

Country Link
US (2) US11306101B2 (es)
EP (1) EP3976595A4 (es)
JP (2) JP7496838B2 (es)
KR (1) KR20250078628A (es)
CN (4) CN118724867A (es)
AR (1) AR119057A1 (es)
AU (1) AU2020282748A1 (es)
BR (1) BR112021022758A2 (es)
CA (1) CA3136753A1 (es)
CL (1) CL2021003134A1 (es)
CO (1) CO2021015624A2 (es)
IL (1) IL288278B2 (es)
MX (1) MX2021014350A (es)
MY (1) MY208545A (es)
PE (1) PE20220569A1 (es)
SG (1) SG11202112872YA (es)
TW (2) TW202523657A (es)
WO (1) WO2020243379A1 (es)
ZA (1) ZA202109003B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250078628A (ko) 2019-05-31 2025-06-02 셀진 코포레이션 치환된 1-옥소-이소인돌린-5-카르복스아미드 화합물, 그의 조성물 및 그를 사용한 치료 방법
JP2023545508A (ja) * 2020-10-14 2023-10-30 シーフォー セラピューティクス， インコーポレイテッド Ｉｋｚｆ２又はｉｋｚｆ４を分解する三環式リガンド
CN112679421A (zh) * 2021-01-04 2021-04-20 都创(上海)医药科技股份有限公司 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法
EP4277901A1 (en) 2021-01-13 2023-11-22 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
EP4333986A1 (en) * 2021-05-06 2024-03-13 Celgene Corporation Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)- 2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1- oxoisoindoline-5-carboxamide
CA3221549A1 (en) * 2021-06-08 2022-12-15 Liqiang Fu Isoindolinone compounds, and uses thereof
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
JP2025509610A (ja) 2022-03-17 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
EP4540238A1 (en) * 2022-06-16 2025-04-23 Monte Rosa Therapeutics AG Molecular glue degraders and methods of using the same
EP4540240A1 (en) * 2022-06-16 2025-04-23 Monte Rosa Therapeutics AG Molecular glue degraders and methods of using the same
WO2024027694A1 (zh) * 2022-08-01 2024-02-08 苏州开拓药业股份有限公司 一种蛋白降解剂
EP4631937A1 (en) * 2022-12-07 2025-10-15 Hangzhou Glubio Pharmaceutical Co., Ltd. Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof
WO2024120438A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 一种固体分散体、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
WO2007027527A2 (en) 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
CL2007002513A1 (es) 2006-08-30 2008-04-04 Celgene Corp Soc Organizada Ba Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
ZA200901078B (en) * 2006-08-30 2010-06-30 Celgene Corp 5-substituted isoindoline compounds
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3331905B1 (en) 2015-08-06 2022-10-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
KR20250078628A (ko) 2019-05-31 2025-06-02 셀진 코포레이션 치환된 1-옥소-이소인돌린-5-카르복스아미드 화합물, 그의 조성물 및 그를 사용한 치료 방법

Also Published As

Publication number Publication date
IL288278B2 (en) 2025-09-01
CN114957212B (zh) 2024-05-24
KR20250078628A (ko) 2025-06-02
CN114957212A (zh) 2022-08-30
EP3976595A4 (en) 2023-01-04
CN118724867A (zh) 2024-10-01
IL288278B1 (en) 2025-05-01
US12486281B2 (en) 2025-12-02
TW202110819A (zh) 2021-03-16
CN119930578A (zh) 2025-05-06
CA3136753A1 (en) 2020-12-03
US20220213115A1 (en) 2022-07-07
WO2020243379A1 (en) 2020-12-03
US11306101B2 (en) 2022-04-19
ZA202109003B (en) 2025-01-29
CL2021003134A1 (es) 2022-07-01
KR20220016167A (ko) 2022-02-08
PE20220569A1 (es) 2022-04-20
SG11202112872YA (en) 2021-12-30
CN114269729A (zh) 2022-04-01
EP3976595A1 (en) 2022-04-06
MY208545A (en) 2025-05-14
IL288278A (en) 2022-01-01
JP2024123001A (ja) 2024-09-10
TW202523657A (zh) 2025-06-16
AR119057A1 (es) 2021-11-17
AU2020282748A1 (en) 2021-12-09
CO2021015624A2 (es) 2022-02-28
US20200377512A1 (en) 2020-12-03
JP7496838B2 (ja) 2024-06-07
CN114269729B (zh) 2025-01-17
JP2022534979A (ja) 2022-08-04
BR112021022758A2 (pt) 2022-03-22
TWI851729B (zh) 2024-08-11

Similar Documents

Publication Publication Date Title
MX2021014350A (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
PH12021551167A1 (en) New heterocyclic compounds
GEP20237506B (en) Pcsk9 antagonist compounds
CR20220251A (es) Nuevos derivados de metilquinazolinona
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
EA202191519A1 (ru) Модуляторы trex1
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
CR20240120A (es) Compuesto inductor de la degradación de PLK1 novedoso
PH12021552555A1 (en) Dihydroorotate dehydrogenase inhibitors
PH12020552206A1 (en) Pyrazole derivatives as malt1 inhibitors
EA202190055A1 (ru) Производные пиразола в качестве ингибиторов malt1
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
MX2020006290A (es) Dinucleotidos ciclicos como agonistas de sting.
EA201991349A1 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
JOP20200291A1 (ar) معدلات التعبير عن apol1
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
BR112022003982A2 (pt) Compostos heterocíclicos
MX2022000811A (es) Inhibidores de enzimas.
JOP20200326A1 (ar) مشتقات تترا هيدرو ثينوبيريدين بها استبدال بـ n واستخداماتها
MX2022000243A (es) Nuevos compuestos heterociclicos.
MX2022002443A (es) Compuestos inhibidores de perk.
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists